Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients

Chest

Volumn 111, Issue 6, 1997, Pages 1778-1781

  Riker, Richard R ^a   Fraser, Gilles L ^a   Richen, Peter ^a  

^a Department of Critical Care Medicine ^*

Author keywords

Benzodiazepines; Critical care; Delirium; Drug induced dyskinesia; Haloperidol; Intensive care unit; Intravenous; Movement disorders; Psychomotor agitation; Tremor

Indexed keywords

HALOPERIDOL;

ADULT; ARTICLE; CLINICAL ARTICLE; DELIRIUM; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; INTENSIVE CARE; MALE; MOTOR DYSFUNCTION; PRIORITY JOURNAL; RESTLESSNESS; TREMOR;

EID: 0030996364     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.111.6.1778     Document Type: Article

References (29)

1. Fish DN. Treatment of delirium in the eritically ill patient. Clin Pharm 1991; 10:456-66
2. Shapiro BA, Warren J, Egol AB, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive cure unit: an executive summary. Crit Care Med 1995; 23:1596-1600
3. Tesar GE, Stern TA. Evaluation and treatment of agitation in the JCU. J Intensive Care Med 1986; 1:137-48
4. Hansen-Flaschen JH, Brazinsky S, Basile C, et al. Use of sedating drugs and neuromusenlar blocking agents in patients requiring mechanical ventilation for respiratory failure. JAMA 1991; 266:2870-75
5. Ziehm SR. Intravenous haloperidol for tranquilization in critical care patients: a review and critique. AACN Clin Issues 1991; 2:765-77
6. Tesur GE, Murray GB, Cassem NH. Use of high-dose intravenous haloperidol in the treatment of agitated cardiac patients. J Clin Psychopharmacol 1985; 5:344-47
7. Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med 1994; 22:433-40
8. Sanders KM, Murray GB, Cassem NH. High dose intravenous haloperidol for agitated delirium in a cardiac patient on intra-aorfic balloon pump. J Clin Psychopharmacol 1991; 11:146-47
9. Metzger E, Friedman R. Prolongation of the corrected QT and torsades des pointes cardiac arrhythmia associated with intravenous haloperidol. J Clin Psychopharmacol 1993; 13:128-32
10. DiSalvo TG, O'Gara PT. Torsades de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol 1995; 18:285-90
11. Shalev A, Hermesh H, Munitz, H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989; 50:18-25
12. Settle EC, Ayd FJ. Haloperidlol: a quarter century of experience. J Clin Psychiatry 1983; 44:440-48
13. Dixon L, Thaker C, Conley R, et al. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophrenia Res 1993; 10:267-71
14. Lieberman J. Cholinergic rebound in neuroleptic withdrawal syndromes [letter]. J Clin Psychiatry 1981; 42:179
15. Eppel AB, Mishra R. The mechanism of neuroleptic withdrawal. Can J Psychiatry 1984; 29:508-09
16. Luchins DL, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 1980; 137:1395-98
17. Nelli AC, Yarden PE, Guazzelli M, et al. Parkinsonism following neuroleptic withdrawal. Arch Gen Psychiatry 1989; 46:383-84
18. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiat Clin North Am 1993; 16:589-610
19. Casey DE. Tardive dyskinesia. West J Med 1990; 153:535-41
20. Adams F. Emergency intravenous sedation of the delirious, medically ill patient. J Clin Psychiatry 1988; 49(suppl):22-6
21. Seneff MG, Mathews RA. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother 1995; 29:690-93
22. Pohlman AS, Simpson KP, Hall JB. Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: a prospective, randomized study. Crit Care Med 1994; 22:1241-47
23. Menza MA, Murray GB, Holmes VF, et al. Decreased extrapyramidal symptoms with intravenous haloperidol. J Clin Psychiatry 1987; 48:278-80
24. Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol 1994; 14:159-62
25. Subramanyam B. Pond SM, Eyles DE, et al. Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol. Biochem Biophys Res Commun 1991; 181:573-78
26. Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986; 315:854-59
27. Rosebush PI, Mazurek MF. Catatonia after benzodiazepine withdrawal. J Clin Psychopharmacol 1996; 16:315-19
28. Lane JC, Tennison MB, Lawless ST, et al. Movement disorder after withdrawal of fentanyl infusion. J Pediatr 1991; 119:649-51
29. Tune L, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149:1393-94